Skip to main content

Tough decisions: How OCM and BPCIA participants managed COVID-19 overlap challenges

The COVID-19 pandemic has impacted every aspect of our healthcare system. That’s true for participants in the Oncology Care Model and Bundled Payments for Care Improvement Advanced programs. Organizations in these programs had to make important decisions regarding the overlap of their program performance periods with the COVID-19 public health emergency.

Several trends have begun to emerge from these choices. Here’s what DataGen’s analysts have seen from the data:

BPCIA

For performance periods that overlapped with the PHE, BPCIA participants had to decide if they would remove all upside and downside risk, or just remove COVID-19 patients from their reconciliation. From our analysis, it appears that decisions were balanced between these two options. We are not aware of any episode initiators who chose to continue their reconciliations as usual with no exclusions at all. Here’s what we believe drove those decisions:
  • Opting out of the performance period reconciliation entirely by removing all upside and downside risk was a safe bet. This was especially true for episode initiators who had a good deal of uncertainty about their BPCIA financials during the PHE. Since all episodes were impacted by the PHE, participants who chose this option are still facing potential financial losses internally.
  • Participants who had positive momentum in BPCIA were attracted to the option to carve out COVID-19 episodes from their reconciliation. Characteristics of participants who considered this option include: not being at risk for clinical episode categories mainly composed of elective procedures, being located in regions less impacted by the PHE and having already implemented noticeable practice transformation to project savings at least among the non-COVID-19 episode population.
  • Going forward as usual with the reconciliation — including all episodes and not carving out COVID-19 patients — required a significant level of confidence in the outcome of the performance period. It’s not surprising that this option wasn’t chosen.

Participants won’t be burdened with this choice moving forward. If the PHE continues and overlaps into model year 4, episodes for COVID-19 patients will be excluded from the reconciliation for all episode initiators.

OCM

For OCM, we saw strong alignment between the level of risk taken on by participants and how they would handle the overlap between performance periods and the PHE. Participants taking on one-sided risk tended to stay in the reconciliation with COVID-19 episodes carved out. This allowed them the opportunity to still earn a performance-based payment. Participants with two-sided risk tended to opt out of the reconciliation entirely to avoid any potential repayments to CMS in the impacted performance periods.

Regardless of those choices, most practices have signed the participation agreement to continue their OCM participation into calendar year 2021 for the two newly added performance periods. These additional periods will help practices continue the work they’ve undertaken to transform their oncology practices while getting the benefit of monthly enhanced oncology services payments to help fund that effort.

We have seen, however, that some practices at two-sided risk are still carefully weighing their options and right to terminate from the program before the next performance period start date. This decision-making process will likely be influenced by whether or not the PHE is extended — which would extend COVID-19 flexibilities. The most recent extension of the PHE will overlap with the start of the next performance period.

The pandemic has had many rippling effects on policy and programmatic changes for alternative payment models. While these changes have given participants flexibility to stay in the programs without risking an undue amount, it will be interesting to see what further changes, if any, happen if the PHE continues to be extended.

Comments

Popular posts from this blog

BPCI Advanced – take advantage of the model extension now

The Bundled Payment for Care Improvement (BPCI) Advanced Model is now open for applications until May 31, 2023. This model provides a unique opportunity to acute care hospitals and physician group practices who are looking to: evaluate their bundle performance; rejoin if they have previously dropped out due to being under a convener; or take advantage of the changes to the model. With a small window to sign the participation agreement, you’ll need experts to process data quickly and accurately for evaluation. BPCI Advanced Program Details The Centers for Medicare & Medicaid Services (CMS) announced in October 2022 that this program will extend from January 2024 to December 2025. Data used for evaluation will be taken from the baseline period between October 2018 and September 2022. A participation agreement will be sent out in September 2023 and needs to be signed by October 2023 in order to participate. Those who apply before the May 31 deadline will benefit

BPCI Advanced Model Extension

CMS recently made several major announcements about the Bundled Payments for Care Improvement Advanced Model.  The model, which was due to expire at the end of 2023 (Model Year 6), will be extended for an additional two years through Dec. 31, 2025.  New applications will be accepted in 2023 for the two-year extension. Participants still active in Model Year 6 can continue without reapplying by signing an amended and restated participation agreement for Model Year 7.  New methodological changes will be implemented for Model Year 6, which starts on Jan. 1, 2023. Methodological changes include that: the CMS Discount Factor for medical clinical episodes will be reduced from 3% to 2%;  the Peer Group Trend Factor Adjustment cap for all clinical episodes will be reduced from 10% to 5%; the Major Joint Replacement of the Upper Extremity clinical episode category will become a multi-setting episode category by allowing episodes to be triggered when the procedure is performed in the hospital ou

You’ve been accepted to the Enhancing Oncology Model. Now what?

The Centers for Medicare and Medicaid Services Innovation Center recently announced approved applicants for the new Enhancing Oncology Model. If your facility has been selected by CMS, are you still weighing your options during the current baseline evaluation period?  Two deciding factors may include the program data that CMS provides and whether EOM is enough of an improvement over the prior Oncology Care Model to make your investment worthwhile. Another factor to consider: Will you have the resources in place to conduct a baseline evaluation before EOM’s program start on July 1, 2023? How EOM differs from OCM EOM aims to improve the coordination of oncology care, drive practice transformation and reduce Medicare fee-for-service spending through episode-based payment. It includes three major updates: Fewer cancer types. Compared with OCM’s 21, EOM will be limited to seven common cancer types: breast, prostate, lung, small intestine/colorectal, multiple myeloma, lymphoma and chronic le